CA2624707A1 - Method for selectively depleting hypoxic cells - Google Patents

Method for selectively depleting hypoxic cells Download PDF

Info

Publication number
CA2624707A1
CA2624707A1 CA002624707A CA2624707A CA2624707A1 CA 2624707 A1 CA2624707 A1 CA 2624707A1 CA 002624707 A CA002624707 A CA 002624707A CA 2624707 A CA2624707 A CA 2624707A CA 2624707 A1 CA2624707 A1 CA 2624707A1
Authority
CA
Canada
Prior art keywords
cells
agent
bone marrow
subject
donor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002624707A
Other languages
English (en)
French (fr)
Inventor
Kalindi Pamar
Peter Mauch
Julian Down
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Bluebird Bio Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2624707A1 publication Critical patent/CA2624707A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002624707A 2005-10-03 2006-09-29 Method for selectively depleting hypoxic cells Abandoned CA2624707A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72318305P 2005-10-03 2005-10-03
US60/723,183 2005-10-03
PCT/US2006/038553 WO2007041546A2 (en) 2005-10-03 2006-09-29 Method for selectively depleting hypoxic cells

Publications (1)

Publication Number Publication Date
CA2624707A1 true CA2624707A1 (en) 2007-04-12

Family

ID=37826084

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002624707A Abandoned CA2624707A1 (en) 2005-10-03 2006-09-29 Method for selectively depleting hypoxic cells

Country Status (5)

Country Link
US (1) US20090136521A1 (https=)
EP (1) EP1931769A2 (https=)
JP (1) JP2009510165A (https=)
CA (1) CA2624707A1 (https=)
WO (1) WO2007041546A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1896040B1 (en) 2005-06-29 2012-08-01 Threshold Pharmaceuticals, Inc. Phosphoramidate alkylator prodrugs
NZ549831A (en) * 2006-09-11 2009-03-31 Auckland Uniservices Ltd Combination of docetaxel and a nitrophenyl phosphate derivative for the treatment of cancer
WO2008033039A1 (en) * 2006-09-11 2008-03-20 Adam Vorn Patterson Cancer treatment
CA2706378C (en) 2007-11-20 2017-09-12 Lankenau Institute For Medical Research Disulfide chemotherapeutic agents and methods of use thereof
CN101683319B (zh) * 2008-09-24 2012-09-05 杭州民生药业有限公司 一种替拉扎明非肠道给药含水制剂及其制备方法
EP2350664B1 (en) * 2008-10-21 2021-05-19 ImmunoGenesis, Inc. Treatment of cancer using the hypoxia activated prodrug th-302 in combination with docetaxel or pemetrexed
US8697391B2 (en) 2009-05-15 2014-04-15 Lankenau Institute For Medical Research Method of determining cell number or viability using hydroxyethyldisulfide
US8269197B2 (en) 2009-07-22 2012-09-18 Intraop Medical Corporation Method and system for electron beam applications
US9393439B2 (en) 2010-03-01 2016-07-19 Intraop Medical Corporation Radiotherapy combined with hypoxic cell sensitizers
ES2877629T3 (es) 2010-07-12 2021-11-17 Immunogenesis Inc Administración de profármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer
EP2793882A4 (en) 2011-12-22 2015-04-29 Threshold Pharmaceuticals Inc ADMINISTRATION OF HYPOXIA-ACTIVATED PRODRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR THE TREATMENT OF CANCER
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
JP2016528217A (ja) 2013-07-26 2016-09-15 スレッショルド ファーマシューティカルズ，インコーポレイテッド 低酸素活性化プロドラッグおよびタキサンの組合せを用いた膵臓癌の治療
US9808011B2 (en) 2014-12-15 2017-11-07 Biovectra Inc. Pentacyclic triterpene compounds and uses thereof
JP7327900B2 (ja) 2015-06-24 2023-08-16 スレッシュホールド ファーマシューティカルズ， インコーポレイテッド アジリジン含有ｄｎａアルキル化剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794742A (fr) * 1972-02-01 1973-07-30 Bayer Ag Nouveaux di-n-oxydes (1,4) de benzo-1,2,4-triazine, leur procede de preparation et leur application comme medicaments et additifs de nutrition
US3957779A (en) * 1972-11-15 1976-05-18 Bayer Aktiengesellschaft Benzo-1,2,4-triazines
US5175287A (en) * 1986-09-25 1992-12-29 S R I International Process for preparing 1,2,4-benzotriazine oxides
US5484612A (en) * 1993-09-22 1996-01-16 The Board Of Trustees Of The Leland Stanford Junior University Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin
US5672702A (en) * 1995-12-04 1997-09-30 Sanofi Process for preparing 3 amino 1, 2, 4-benzotriazine dioxide
EP1014990B1 (en) * 1997-03-07 2006-09-06 Sanofi-Aventis U.S. LLC Antitumor combination of 3-amino-1,2,4-benzotriazine 1,4-dioxide/paclitaxel/platinum
CN1357048A (zh) * 1998-03-06 2002-07-03 牛津生物医学（英国）有限公司 增强前体药物活化

Also Published As

Publication number Publication date
WO2007041546A2 (en) 2007-04-12
US20090136521A1 (en) 2009-05-28
WO2007041546A3 (en) 2007-07-12
EP1931769A2 (en) 2008-06-18
JP2009510165A (ja) 2009-03-12

Similar Documents

Publication Publication Date Title
Neben et al. Mobilization of hematopoietic stem and progenitor cell subpopulations from the marrow to the blood of mice following cyclophosphamide and/or granulocyte colony-stimulating factor
Bonnet et al. Cytokine treatment or accessory cells are required to initiate engraftment of purified primitive human hematopoietic cells transplanted at limiting doses into NOD/SCID mice
US20090136521A1 (en) Method for Selectively Depleting Hypoxic Cells
DE60302231T2 (de) Transplant-akzeptanz induzierende zellen monocytären ursprungs, sowie deren herstellung und verwendung
US9545427B2 (en) Therapeutic uses of allogeneic myeloid progenitor cells
Kim et al. Stress-associated erythropoiesis initiation is regulated by type 1 conventional dendritic cells
Szilvassy et al. Effects of cell cycle activation on the short-term engraftment properties of ex vivo expanded murine hematopoietic cells
US12415987B2 (en) Methods and composition for producing and using immune cells and stem cells for cell-based therapies
Szade et al. Cobalt protoporphyrin IX increases endogenous G‐CSF and mobilizes HSC and granulocytes to the blood
US10570373B2 (en) Post-natal hematopoeitic endothelial cells and their isolation and use
Stiff et al. Anti-CD33 monoclonal antibody and etoposide/cytosine arabinoside combinations for the ex vivo purification of bone marrow in acute nonlymphocytic leukemia
Chen et al. Defective stromal cell function in a mouse model of infusion-induced bone marrow failure
JP7764513B2 (ja) 抗癌活性が増大されたナチュラルキラー細胞、及びその免疫治療用途
Scheffold et al. Cytokines and cytotoxic pathways in engraftment resistance to purified allogeneic hematopoietic stem cells
US20040005300A1 (en) Methods for enhancing engraftment of purified hematopoietic stem cells in allogeneic recipients
Skinner et al. CXCR4 induction in hematopoietic progenitor cells from Fanca−/−,-c−/−, and-d2−/− mice
US20260027155A1 (en) Compositions and methods related to potent cytotoxic m-cenk cells from cd3/cd14-depleted apheresis products
Neben et al. Mobilization of hematopoietic stem and progenitor cell
WO2025045868A1 (en) Compositions for use in a method of providing improved hematopoietic stem cell engraftment
Storb 1Hematopoietic Stem Cell Transplantation: Yesterday, Today and Tomorrow
CA2375527A1 (en) Method for enhancing hematopoiesis
Yeoh et al. Mobilized peripheral blood stem cells provide rapid reconstitution but impaired long-term engraftment
Baumann et al. THE FISHER-LEWIS KIDNEY TRANSPLANTATION MODEL AS TOOL TO INVESTIGATE TRANSPLANT-RELATED CARDIOMYOPATHY: 1508
Hüser et al. REQUIREMENT OF LFA-1 DE-ACTIVATION FOR CARDIAC ALLOGRAFT REJECTION: 1509
Kucia et al. Hematopoietic stem cells from NOD mice exhibit autonomous behavior and

Legal Events

Date Code Title Description
FZDE Discontinued